Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: A post hoc analysis (ORIENT-blood pressure)

Nephrology Dialysis Transplantation

Volumn 31, Issue 3, 2016, Pages 447-454

  Imai, Enyu ^a,b   Ito, Sadayoshi ^c   Haneda, Masakazu ^d   Harada, Atsushi ^e   Kobayashi, Fumiaki ^e   Yamasaki, Tetsu ^e   Makino, Hirofumi ^f   Chan, Juliana C N ^g  

^a Nakayamadera Imai Clinic   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

^e DAIICHI SANKYO CO   (Japan)

^f OKAYAMA UNIVERSITY   (Japan)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

cardiovascular outcome; diabetic nephropathy; proteinuria; renal outcome; systolic blood pressure

Indexed keywords

CREATININE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE SEVERITY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LEG AMPUTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; REVASCULARIZATION; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; HONG KONG; JAPAN; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRENDS;

ADULT; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HONG KONG; HUMANS; JAPAN; MALE; MIDDLE AGED; MORBIDITY;

EID: 84960123509     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv272     Document Type: Article

References (40)

1. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123: 2799-2810
2. Khouri Y, Steigerwalt SP, AlsamaraMet al. What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease? Curr Cardiol Rep 2011; 13: 492-501
3. Allen M, Kelly K, Fleming K. Uncertainty about the systolic blood pressure target in people with diabetes. Can Fam Physician 2013; 59: 128-131
4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913
5. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169
6. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21: 707-716
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
8. ACCORD Study Group, Cushuman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585
9. American Diabetes Association. Standards for medical care in diabetes-2013. Diabetes Care 2013; 36: S11-S66
10. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012; 2: 337-414
11. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520
12. Bakris GL, Weir MR, Shanifar S, et al. RENAAL Study Group: effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555-1565
13. Berl T, Hunsicker LG, Lewis JB, et al. Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 2170-2179
14. Kong AP, Xu G, Brown N, et al. Diabetes and its comorbidities-where east meets west. Nat Rev Endocrinol 2013; 9: 537-547
15. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54: 2978-2986
16. Greenland S. Introduction to regression models. In: Rothman KJ, Greenland S, Lash TL (eds). Modern Epidemiology. 3rd edn. Philadelphia: Lippincott-Williams-Wilkins, 2008, pp. 381-417
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
18. Mastuo S, Imai E, HorioMet al. Revised equations for estimating glomerular filtration rate (GFR) from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992
19. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl JMed 2006; 354: 2473-2483
20. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037
21. Uzu T, Kida Y, Yamauchi A, et al. The effects of blood pressure control levels on the renoprotection of type 2 diabetic patients without overt proteinuria. J Am Soc Hypertens 2012; 6: 124-131
22. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884
23. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252
24. Koop K, EikmansM, WehlandMet al. Selective loss of podoplanin protein expression accompanies proteinuria and precedes alterations in podocyte morphology in a spontaneous proteinuric rat model. Am J Pathol 2008; 173: 315-326
25. Yang L, Brozovic S, Xu J, et al. Inflammatory gene expression in overt diabetic kidney during the development of nephropathy. Nephron Exp Nephrol 2011; 119: e8-e20
26. Holtkamp FA, de Zeeuw D, de Graeff PA, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011; 32: 1493-1499
27. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892-1903
28. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313: 603-615
29. Nakayama M, Metoki H, Terawaki Het al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transplant 2007; 22: 1910-1915
30. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004; 25: 971-1010
31. Mooyaart AL, Valk EJ, van Es LA, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia 2011; 54: 544-553
32. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl 2): S14-S21
33. Chan JC, Wat NM, So WY, et al. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. Diabetes Care 2004; 27: 874-879
34. Kurokawa K, Chan JC, Cooper ME, et al. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL Study. Clin Exp Nephrol 2006; 10: 193-200
35. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
36. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
37. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
38. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
39. Haller H, Ito S, Izzo JL, Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
40. Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors' expert forum. Diabetes Care 2013; 36: 1779-1788